



02-11-05

IFW

Docket 17322 CON2CIP1 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
EVAN B. DREYER

Serial No: 10/734,930

Filed: December 12, 2003

For: CALCIUM BLOCKERS TO
TREAT PROLIFERATIVE RETINAL
DISEASES

Group Art Unit: 1614

Examiner: Fay, Zohreh A

Confirmation No. 2241

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled **CALCIUM BLOCKERS TO TREAT PROLIVERATIVE RETINAL DISEASES**, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.



Docket 17233CON2CIP1 (AP)

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,


Date: February 9, 2005


Brent A. Johnson
Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

I hereby certify that this Supplemental Information Disclosure Statement and additional documents enclosed herein are being deposited with the United States Postal Service on **February 9, 2005** in an envelope as "Express Mail Post Office To Addressee" mailing label number **EV295681911US** with sufficient postage for Express Mail addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Susan Bartholomew
Name of person mailing paper

Susan Bartholomew
Signature of person mailing paper

Date: February 9, 2005

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP1 (APP) APR 14 2005 FEB 09 2005 PATENT & TRADEMARK OFFICE	SERIAL NO.: 10/734,930
APPLICANTS: Evan B. Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIVERATIVE RETINAL DISEASES
FILING DATE: 12/12/03	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA	4,755,388	7/5/1988	Papahadjopoulos			
AB	5,424,321	6/13/1995	Hellberg, et al.			
AC	5,516,522	5/14/1996	Peyman, et al.			
AD	5,597,809	1/28/1997	Dreyer			
AE	5,602,156	2/11/1997	Kohn			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA	WO 90/06118	6/14/1990	PCT			
BB	WO 91/02497	3/07/1991	PCT			
BC	WO 94/13275	6/23/1994	PCT			
BD	WO 95/22979	8/31/1995	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Ehren, M., et al., <i>Inhibition of RPE proliferation, attachment and migration by carboxyamido-triazole (CAI), a drug which acts by modifying calcium mediated signal transduction</i> , Investigative Ophthalmology and Visual Science, Vol. 38, No. 4 part 1-2 May 1997, pg. S754
CB	Hahn, J.M., et al., <i>Calcium channel blocker mediated inhibition of retinal pigment epithelial cell contraction of a collagen gels</i> , Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 1996, pg. S393
CC	Hoffmann, S., et al., <i>Effect of the Calcium-antagonist verapamil on the serum induced proliferation of RPE cells in vitro</i> , Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 1996, pgs. S389
CD	Richter D., et al. <i>Growth inhibition of intraocular proliferative explants under in vitro conditions by verapamil</i> , Klinische Monatsblatter Fur Augenheilkunde, Sep 1993, Vol. 203, No. 3, pgs. 206-211

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.